2002•ACP Journal ClubRequires access

Tenecteplase plus enoxaparin or abciximab was better than tenecteplase plus unfractionated heparin for acute MI

Steven L. Borzak, Steven L. Borzak

Abstract

Source Citation The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001 Aug 25;358:605-13. 11530146

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Tenecteplase, Medicine, Abciximab, Heparin, Myocardial infarction, Regimen, Fibrinolytic agent, Internal medicine